AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-9.46%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$3.4B
AUM Growth
+$3.4B
(-16%)
Cap. Flow
+$6.27M
Cap. Flow
% of AUM
0.18%
Top 10 Holdings %
Top 10 Hldgs %
45.82%
Holding
159
New
12
Increased
20
Reduced
9
Closed
8
Top Buys
| 1 |
Kymera Therapeutics
KYMR
|
$38.1M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$29.3M |
| 3 |
Evotec
EVO
|
$27.3M |
| 4 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$27.3M |
| 5 |
BLU
BELLUS Health Inc.
BLU
|
$26.2M |
Top Sells
| 1 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$172M |
| 2 |
argenx
ARGX
|
$27.1M |
| 3 |
iTeos Therapeutics
ITOS
|
$21M |
| 4 |
Alibaba
BABA
|
$14.8M |
| 5 |
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
|
$14.1M |
Sector Composition
| 1 | Healthcare | 90.88% |
| 2 | Consumer Discretionary | 7.05% |
| 3 | Materials | 0.52% |
| 4 | Financials | 0.38% |
| 5 | Consumer Staples | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Lexicon Pharmaceuticals
LXRX
$400M
| $280M | 7.61% | 71,178,364 | – | – |
|
|
WW
2
DELISTED
WW International
WW
| $239M | 6.49% | 14,818,300 | – | – |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $205M | 5.57% | 1,400,000 +200,000 | +17% | +$29.3M |
|
|
ONC
4
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $183M | 4.96% | 675,000 +25,000 | +4% | +$6.77M |
|
|
5
argenx
ARGX
$43.6B
| $175M | 4.75% | 500,000 -77,308 | -13% | -$27.1M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $110M | 2.99% | 650,000 -50,000 | -7% | -$8.48M |
|
7
Seer Inc
SEER
$115M
| $108M | 2.94% | 4,750,000 | – | – |
|
8
Fate Therapeutics
FATE
$120M
| $105M | 2.86% | 1,800,000 +350,000 | +24% | +$20.5M |
|
|
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
| $77.3M | 2.1% | 500,000 +125,000 | +33% | +$19.3M |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $75.1M | 2.04% | 1,585,049 | – | – |
|
11
Amicus Therapeutics
FOLD
$2.34B
| $69.3M | 1.88% | 6,000,000 -696,955 | -10% | -$8.05M |
|
|
BLU
12
DELISTED
BELLUS Health Inc.
BLU
| $68.4M | 1.86% | 8,500,000 +3,250,000 | +62% | +$26.2M |
|
|
13
Kymera Therapeutics
KYMR
$2.95B
| $63.5M | 1.72% | 1,000,000 +600,000 | +150% | +$38.1M |
|
14
Scholar Rock
SRRK
$3.14B
| $60.9M | 1.65% | 2,450,000 +500,000 | +26% | +$12.4M |
|
|
SWTX
15
DELISTED
SpringWorks Therapeutics
SWTX
| $52.7M | 1.43% | 850,000 +250,000 | +42% | +$15.5M |
|
16
Erasca
ERAS
$445M
| $49.4M | 1.34% | 3,172,221 | – | – |
|
17
Krystal Biotech
KRYS
$4.27B
| $49M | 1.33% | 700,000 +200,000 | +40% | +$14M |
|
|
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $48.6M | 1.32% | 1,500,000 -300,000 | -17% | -$9.73M |
|
19
Cytokinetics
CYTK
$4.23B
| $45.6M | 1.24% | 1,000,000 -300,000 | -23% | -$13.7M |
|
|
IGMS
20
DELISTED
IGM Biosciences
IGMS
| $44M | 1.19% | 1,500,000 +150,000 | +11% | +$4.4M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $42.8M | 1.16% | 1,250,000 -250,000 | -17% | -$8.55M |
|
|
SAGE
22
DELISTED
Sage Therapeutics
SAGE
| $42.5M | 1.15% | 1,000,000 | – | – |
|
|
IMAB
23
I-MAB
IMAB
$340M
| $40.3M | 1.09% | 850,000 +25,000 | +3% | +$1.18M |
|
24
Foghorn Therapeutics
FHTX
$286M
| $39.4M | 1.07% | 1,720,720 | – | – |
|
|
RUBY
25
DELISTED
Rubius Therapeutics, Inc
RUBY
| $35.8M | 0.97% | 3,701,580 -454,045 | -11% | -$4.4M |
|